MONUROL Drug Patent Profile

« Back to Dashboard

When do Monurol patents expire, and what generic alternatives are available?

Monurol is a drug marketed by Zambon Spa and is included in one NDA.

The generic ingredient in MONUROL is fosfomycin tromethamine. There is one drug master file entry for this compound. Ten suppliers are listed for this compound. Additional details are available on the fosfomycin tromethamine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Monurol

A generic version of MONUROL was approved as fosfomycin tromethamine by XIROMED on October 6^th, 2020.

Summary for MONUROL

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	51
Clinical Trials:	4
Patent Applications:	708
Drug Prices:	Drug price information for MONUROL
What excipients (inactive ingredients) are in MONUROL?	MONUROL excipients list
DailyMed Link:	MONUROL at DailyMed

See drug prices for MONUROL

Recent Clinical Trials for MONUROL

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Gerencia de Atención Primaria, Madrid	Phase 4
Jordi Gol i Gurina Foundation	Phase 4
Balearic Islands Health Service (Ibsalut)	Phase 4

See all MONUROL clinical trials

US Patents and Regulatory Information for MONUROL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Zambon Spa	MONUROL	fosfomycin tromethamine	FOR SOLUTION;ORAL	050717-001	Dec 19, 1996		DISCN	Yes	No

Monurol Market Dynamics, Financial Trajectory, Patent Position, and Generic Entry Risk

Last updated: November 2, 2026

Monurol, the U.S. brand for fosfomycin tromethamine, is a mature oral antibiotic used as a single 3-gram dose for uncomplicated urinary tract infections in women. Its commercial profile is defined by an established FDA approval, limited labeled use, low current patent protection, generic substitution risk, and persistent demand linked to antimicrobial resistance. Public disclosures do not provide a separate Monurol revenue line, so its financial trajectory is best assessed through prescription demand, pricing, supply, competition, and the broader fosfomycin market rather than reported brand sales.

What is Monurol and how is it used?

Monurol contains fosfomycin tromethamine, an oral formulation of fosfomycin. The FDA-approved product is supplied as a single-dose 3-gram packet of granules dissolved in water. It is indicated for acute uncomplicated cystitis in women caused by susceptible strains of Escherichia coli and Enterococcus faecalis.[1]

Attribute	Monurol profile
Active ingredient	Fosfomycin tromethamine
Dosage form	Oral granules in a single-dose sachet
Strength	3 grams
FDA application	NDA 050717
U.S. approval	December 1996
Primary indication	Acute uncomplicated cystitis in women
Administration	One 3-gram oral dose
U.S. sponsor	Zambon Group S.p.A.
Drug class	Epoxide antibiotic
Biosimilar relevance	None; Monurol is a small-molecule drug

Fosfomycin inhibits MurA, an enzyme involved in the first stage of bacterial cell-wall synthesis. Its mechanism differs from commonly used oral urinary antibiotics, including nitrofurantoin and trimethoprim-sulfamethoxazole. That difference supports continued clinical use when resistance limits other oral options.[1,2]

Monurol is not a broad substitute for all urinary tract infection therapies. The FDA label does not cover pyelonephritis, complicated urinary tract infection, or systemic infections. Treatment guidelines also restrict its role in some resistant infections and do not generally position oral fosfomycin as a universal first-line antibiotic.[2]

What is the FDA regulatory status of Monurol?

Monurol remains an FDA-approved prescription product under NDA 050717. Its U.S. regulatory value comes from the established label, manufacturing history, and clinical familiarity rather than active regulatory exclusivity.

FDA approval timeline

Milestone	Date
FDA approval of Monurol NDA 050717	December 19, 1996
Current product category	Approved prescription antibiotic
New chemical entity exclusivity	Expired
Orphan exclusivity	Not applicable
Pediatric exclusivity	Not a current commercial protection
Current U.S. commercial protection	Primarily regulatory approval and brand recognition

The product’s single-dose administration provides a practical advantage over multi-day regimens. The commercial limitation is the narrow labeled population. Monurol does not capture the full urinary tract infection market because many patients receive nitrofurantoin, trimethoprim-sulfamethoxazole, beta-lactams, or fluoroquinolones.

What patents protect Monurol?

No material unexpired composition-of-matter patent should be expected to protect Monurol in the United States. Fosfomycin was discovered in the 1960s, and the original compound and early pharmaceutical rights are long past their normal patent terms.

The remaining intellectual-property question is whether later patents cover the specific oral sachet, excipient system, manufacturing process, or a new use. Those rights would need to be evaluated separately from the underlying fosfomycin molecule. The historical product estate does not create a meaningful modern barrier to generic development.

Patent category	Current commercial significance
Fosfomycin composition patent	Expired
Fosfomycin tromethamine product protection	Expected to be expired
Single-dose cystitis method claims	Generally vulnerable to expiration and invalidity challenges
Oral granule formulation claims	Potentially relevant only if an unexpired claim remains
Manufacturing process claims	May affect API sourcing, but are not expected to block the molecule broadly
U.S. Orange Book patent protection	No meaningful current protection identified for commercial planning

The FDA Orange Book is the controlling source for patents listed against an approved product. A generic applicant can pursue an Abbreviated New Drug Application with a Paragraph IV certification if it believes a listed patent is invalid, unenforceable, or not infringed.[3]

When does Monurol lose exclusivity?

Monurol lost meaningful market exclusivity years ago. Its current commercial position is not based on an active patent or exclusivity period.

The relevant distinction is between regulatory approval and commercial exclusivity:

• FDA approval remains in place.
• New chemical entity exclusivity has expired.
• Any original composition patent has expired.
• A generic applicant can seek approval through the ANDA pathway.
• A later formulation or manufacturing patent, if listed and unexpired, could delay approval or launch but would not restore molecule-level exclusivity.

For investors and licensing teams, Monurol should therefore be modeled as a mature branded antibiotic with generic-entry exposure rather than as a protected specialty product.

How many patents cover Monurol?

The practical answer is zero or a very small number of commercially meaningful unexpired U.S. patents. Historical patents may appear in patent databases, but expired patents do not support current exclusionary pricing.

Patent-count analysis is less important for Monurol than claim scope. A single unexpired formulation patent could affect an ANDA, while dozens of expired historical patents would have no blocking value. The key diligence items are:

1. Current Orange Book entries for NDA 050717.
2. Any litigation associated with listed patents.
3. Whether a generic applicant is seeking approval for the same 3-gram oral granule product.
4. Whether the proposed generic uses a materially different excipient or manufacturing process.
5. Patent coverage in non-U.S. markets where term rules and product registrations differ.

What is the Orange Book status of Monurol?

Monurol is an FDA-approved small-molecule product. The Orange Book determines therapeutic-equivalence ratings for approved generic products and identifies patents or exclusivity associated with the reference product.

Commercial diligence should distinguish among three conditions:

Orange Book condition	Commercial implication
No unexpired listed patent	Generic approval and launch face no Orange Book patent stay
Unexpired listed patent	Paragraph IV litigation could impose a 30-month stay
No marketed generic despite expired protection	Supply, economics, or regulatory execution may be the barrier

The absence of a current generic does not prove that Monurol retains patent protection. Low expected revenue, limited market size, API sourcing complexity, and the cost of establishing a U.S. product may be more important barriers than intellectual property.

Which companies are challenging Monurol?

No major current U.S. Paragraph IV campaign is established by the core FDA approval record alone. Paragraph IV activity must be confirmed through ANDA litigation records, district court filings, and Orange Book patent notices.

The generic competitive set may include manufacturers of fosfomycin tromethamine oral sachets in markets where generic versions are registered. Global availability does not automatically establish U.S. approval. Each manufacturer must satisfy FDA requirements for pharmaceutical equivalence, bioequivalence, manufacturing quality, labeling, and facility compliance.

A generic competitor would likely target the same 3-gram single-dose packet. The primary competitive advantages would be lower price, payer coverage, and reliable supply rather than clinical differentiation.

What generic entry risks exist for Monurol?

Generic entry risk is high in principle and moderate in practical timing. The molecule is old, the product has a narrow formulation, and the principal regulatory pathway is an ANDA. The commercial question is whether the expected sales justify development and launch costs.

Generic launch scenarios

Scenario	Timing profile	Commercial effect
No U.S. generic launch	Indefinite	Brand retains niche demand and pricing power
One generic entrant	12 to 24 months after approval and launch	Price erosion and pharmacy substitution
Multiple generic entrants	Usually after initial market validation	Steeper price decline and lower brand share
Authorized generic or brand price response	At or after generic launch	Slows share loss but reduces net price
Supply disruption at generic manufacturer	Variable	Temporary demand recovery for Monurol

A first generic may not immediately eliminate branded demand. Some providers retain Monurol because of familiarity, single-dose convenience, or payer-specific coverage. Pharmacy substitution and formulary economics usually make long-term brand share loss likely once an interchangeable generic is available.

What is the market size and financial trajectory for Monurol?

Publicly available company disclosures do not separately report Monurol revenue, units, gross margin, or geographic profitability. That prevents a defensible point estimate for annual brand sales or a precise revenue forecast.

The financial trajectory can still be characterized:

Financial driver	Direction for Monurol
Volume demand	Stable to modestly positive in resistant UTI niches
Price growth	Limited by generic risk and payer controls
Gross margin	Potentially attractive while brand pricing persists
Brand investment	Likely low because of product maturity
Regulatory spending	Maintenance-focused
Manufacturing economics	Sensitive to API and sachet supply
Long-term revenue	At risk from substitution and reimbursement pressure

Demand has structural support from antimicrobial resistance. Fosfomycin retains activity against some multidrug-resistant urinary pathogens, including certain extended-spectrum beta-lactamase-producing organisms. Clinical guidance, however, limits use according to infection site, pathogen susceptibility, and patient characteristics.[2,4]

Monurol’s revenue base is likely concentrated in mature markets with established diagnostic and prescribing systems. The product is less likely to produce rapid growth because it has no broad label expansion, no biologic exclusivity, and no premium delivery technology.

How does Monurol compare with competing UTI antibiotics?

Monurol competes primarily on convenience and activity against selected resistant pathogens.

Product	Main advantage	Main limitation
Monurol	Single-dose oral treatment; distinct mechanism	Narrow indication and susceptibility limitations
Nitrofurantoin	Common first-line option; low resistance in many settings	Multi-day course; unsuitable for some renal or systemic conditions
Trimethoprim-sulfamethoxazole	Familiar oral therapy	Resistance and allergy constraints
Oral beta-lactams	Broad prescribing familiarity	Often lower efficacy for uncomplicated cystitis and longer courses
Fluoroquinolones	High tissue penetration	Safety restrictions and stewardship pressure

Monurol’s value is strongest when adherence is a concern, resistance narrows oral options, or a single-dose regimen has a clinical or operational benefit. Its value is weaker where low-cost generic nitrofurantoin is effective and preferred by treatment guidelines.

What formulation patents protect Monurol?

The commercial product uses a water-dissolved granular sachet containing fosfomycin tromethamine. Potential formulation issues include particle size, granule stability, taste masking, dissolution, packaging moisture protection, and dose uniformity.

These features can create technical development work but do not necessarily create durable patent barriers. A generic manufacturer may use a different excipient system while matching the reference product’s pharmaceutical performance. The most important manufacturing risks are:

• Consistent fosfomycin tromethamine API quality.
• Control of moisture and degradation.
• Uniform filling of the 3-gram sachet.
• Acceptable dissolution and palatability.
• Validated analytical methods.
• Reliable supply of packaging components.

The product’s simple oral presentation reduces formulation complexity compared with modified-release or sterile products. That supports eventual generic competition.

What manufacturing and geographic barriers affect Monurol?

Fosfomycin API production and quality control can be more important than patent protection. Manufacturers must qualify suppliers, demonstrate process control, and maintain compliance across API and finished-dose facilities.

Geographic market conditions differ:

Region	Market characteristic
United States	FDA-approved brand; generic-entry economics determine competition
Europe	Fosfomycin has broader clinical visibility, including intravenous products in some markets
Asia-Pacific	Generic availability and local registration practices vary significantly
Latin America	Brand and generic penetration differ by country
Hospital markets	Intravenous fosfomycin can be more important than oral Monurol
Retail pharmacy markets	Oral sachet pricing and substitution dominate

Oral Monurol should not be valued using total global fosfomycin sales. That broader category may include intravenous fosfomycin, hospital products, combination therapies, and veterinary applications.

What biosimilar risk applies to Monurol?

No biosimilar risk applies. Monurol is a chemically synthesized small molecule, not a biologic. Competition proceeds through generic-drug pathways, principally ANDAs in the United States, rather than through biosimilar applications under the Public Health Service Act.

This distinction matters commercially. Generic applicants do not need to reproduce a biologic manufacturing platform or conduct an extensive biosimilar comparability program. The principal requirements are pharmaceutical equivalence, bioequivalence, quality manufacturing, and compliant labeling.

What patent litigation and settlement agreements affect Monurol?

No material current settlement agreement or high-profile U.S. patent litigation is established for Monurol based on the core FDA product record. If a future ANDA applicant files a Paragraph IV certification against a listed patent, the NDA holder could sue within 45 days and obtain a potential 30-month approval stay under the Hatch-Waxman framework.[3]

The commercial impact of any settlement would depend on:

• The patent’s actual expiration date.
• Whether the generic receives a licensed launch date.
• Any authorized-generic arrangement.
• Volume or supply restrictions.
• The number of other ANDA applicants.
• Whether the settlement attracts antitrust scrutiny.

Because Monurol has a mature, low-complexity product profile, a settlement would be more likely to affect timing than to create a durable market barrier.

Key Takeaways

• Monurol is fosfomycin tromethamine 3-gram oral granules for single-dose treatment of uncomplicated cystitis in women.
• FDA approval dates to 1996, and active molecule-level exclusivity has expired.
• The product has no biosimilar exposure; its principal competitive threat is generic substitution.
• A separate Monurol revenue line is not publicly disclosed, preventing a reliable brand-specific financial estimate.
• Demand has support from antimicrobial resistance, but the label and treatment guidelines limit the addressable market.
• The strongest commercial risks are generic entry, price erosion, payer substitution, and supply-chain constraints.
• Formulation and manufacturing requirements may delay a generic launch but are unlikely to create a durable exclusionary barrier.
• Monurol is best modeled as a mature niche antibiotic with stable-to-declining long-term revenue and episodic demand support from resistance trends.

FAQs

Is Monurol still available in the United States?

Monurol remains an FDA-approved product under NDA 050717. Actual retail availability can vary with distributor inventory, pharmacy purchasing, and manufacturing supply.

Is fosfomycin the same as Monurol?

Fosfomycin is the active antibacterial substance. Monurol is the branded oral fosfomycin tromethamine product approved for a specific urinary tract infection indication.

Can Monurol treat kidney infections?

The FDA-approved Monurol label is for acute uncomplicated cystitis and does not cover pyelonephritis. Kidney infections generally require a treatment strategy with adequate renal tissue penetration.[1]

Does Monurol have a patent blocking generic fosfomycin?

The underlying fosfomycin molecule is long off patent. Any current blocking issue would have to arise from a later listed formulation, method, or manufacturing patent, not from the original compound.

Why has a generic Monurol not necessarily displaced the brand?

Approval and commercial launch are separate decisions. A generic manufacturer may avoid the product if expected volume, pricing, API sourcing, regulatory costs, or supply obligations do not support an adequate return.

References

1. U.S. Food and Drug Administration. (1996). Monurol (fosfomycin tromethamine) prescribing information. NDA 050717.

2. Infectious Diseases Society of America. (2024). Guidance on the treatment of antimicrobial-resistant gram-negative infections. Infectious Diseases Society of America.

3. U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.

4. World Health Organization. (2023). The WHO AWaRe antibiotic book: Antibiotic book. World Health Organization.